Keyword: Dicerna Pharmaceuticals
Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis, to the tune of $225 million.
The deal, which will see Roche and Dicerna collaborate on other hepatitis B virus assets, is worth up to $1.5 billion in milestones.
Fresh off a deal with Alexion last week, Dicerna has started off this week with another deal—this time with Eli Lilly.
The deal gives Alexion the rights to two preclinical assets, plus an option on two more, in return for $22 million upfront.
Dicerna and Alnylam are settling a yearslong spat over trade secrets relating to gene-silencing technology.
The pact sees Boehringer commit to up to €307 million to work with MiNA on up to three targets relevant to NASH and other fibrotic liver diseases.
The goal is to use Dicerna’s GalXC technology to silence previously inaccessible drug targets, thereby restoring liver function.